Tesamorelin vs Ipamorelin Classification Differences

Tesamorelin vs ipamorelin classification differences come down to which part of the growth hormone release pathway each peptide is built to interact with. The two compounds are frequently listed side by side in peptide catalogues, but they belong to separate structural and mechanistic classes: tesamorelin is categorized as a growth hormone-releasing hormone (GHRH) analog, while ipamorelin is categorized as a growth hormone secretagogue (GHS) of the growth hormone-releasing peptide (GHRP) family. Understanding that classification split explains why reference material for the two compounds is described so differently across specification sheets, even when both are marketed toward the same general area of research.

Two Different Structural Classes

Tesamorelin is a synthetic 44-amino acid peptide that mirrors the structure of native human GHRH, with a stabilizing modification at the N-terminus that resists rapid enzymatic breakdown. Because it is built from the GHRH sequence itself, it is classified alongside other GHRH analogs, a category defined by peptides that closely replicate the endogenous hormone’s amino acid backbone.

Ipamorelin, by contrast, is a synthetic pentapeptide — five amino acids — that does not resemble GHRH structurally at all. It was designed as a selective ghrelin receptor agonist, placing it in the GHRP/GHS class rather than the GHRH-analog class. This structural gap is the first and most fundamental classification difference between the two: one is a long-chain analog of a natural releasing hormone, and the other is a short synthetic peptide built around a different receptor target entirely.

Receptor Mechanism Comparison

The structural classification maps directly onto a receptor-level distinction, which is the detail most specification sheets use to categorize the two compounds.

Property	Tesamorelin	Ipamorelin
Peptide class	GHRH analog	GHRP / ghrelin receptor agonist (GHS)
Chain length	44 amino acids	5 amino acids
Primary receptor target	GHRH receptor (GHRH-R)	Growth hormone secretagogue receptor (GHS-R1a)
Structural basis	Modified native GHRH sequence	Synthetic sequence, not GHRH-derived
Selectivity note commonly listed	Acts on the GHRH pathway specifically	Described as selective for GH release with minimal effect on other pituitary hormones

Because the two peptides act on different receptors, listings that group them under a single “growth hormone peptide” heading are using a functional category, not a mechanistic one. Reference material that distinguishes GHRH analogs from GHS/GHRP compounds is applying the more precise classification standard, which is the one used in most formal peptide nomenclature.

Why the Classification Distinction Shows Up in Listings

This tesamorelin vs ipamorelin classification difference is why catalogue descriptions for the two peptides rarely use interchangeable language, even on sites that sell both. A listing for tesamorelin will typically reference its GHRH-analog status and its longer amino acid sequence, since that sequence length is itself a verifiable identifying property tied to the compound’s molecular weight. A listing for ipamorelin will more often reference its pentapeptide structure and its receptor selectivity relative to older, less selective GHRP compounds. Readers comparing specification sheets across sites, including catalogue pages such as the one covering tesamorelin, can use this classification language as a consistency check — a sheet describing tesamorelin as anything other than a GHRH analog, or ipamorelin as anything other than a GHS/GHRP, is likely using loose or inaccurate terminology.

The distinction also affects how vial specifications are typically presented. Because tesamorelin’s larger amino acid chain gives it a higher molecular weight than ipamorelin’s five-residue structure, a vial of each compound labeled at the same peptide mg figure does not represent the same molar quantity of peptide. This is a classification-driven detail rather than a manufacturing inconsistency, and it is one reason cost and format comparisons across compounds, such as those tracked across peer tesamorelin listing catalogs, tend to discuss tesamorelin’s vial pricing on its own terms rather than against a shared per-mg benchmark with unrelated peptide classes.

A Worked Example: Reading a Classification-Consistent Vial Label

Because the two compounds are classified separately, their listed peptide content is calculated the same way — from labeled mg per vial — regardless of chain length. The chain length affects molecular weight, not the mg-to-concentration math itself. Take a tesamorelin vial labeled 10 mg, reconstituted with 4 mL of bacteriostatic water:

concentration = 10 mg ÷ 4 mL = 2.5 mg/mL

Converting to micrograms: 2.5 mg/mL × 1000 mcg/mg = 2500 mcg/mL. On a U-100 insulin syringe, where 1 mL equals 100 units and each unit therefore equals 0.01 mL, one unit draws 0.01 mL × 2500 mcg/mL = 25 mcg. Checking this a second way: 10 mg total peptide equals 10,000 mcg, and a 4 mL fill drawn in 0.01 mL increments yields 400 unit-equivalents across the vial, so 10,000 mcg ÷ 400 units = 25 mcg per unit — matching the first calculation. This mg-based approach applies the same way to an ipamorelin vial’s labeled strength; the classification difference between the two peptides does not change the arithmetic, only the identity and molecular weight of the material being measured. A reconstitution calculator such as peptcalc.com can be used to cross-check figures like these against a vial’s printed label.

Checking Which Class a Listing Is Describing

Because “growth hormone peptide” is sometimes used as an umbrella term, the more reliable way to confirm a listing’s classification is to check whether it names a receptor target or a structural family rather than relying on the marketing category alone. A specification sheet that identifies GHRH-R as the target, or that references a 44-amino acid sequence, is describing tesamorelin’s class. A sheet that identifies GHS-R1a, or that describes a short synthetic sequence built for receptor selectivity, is describing ipamorelin’s class. Vial format and sourcing pages, including the listings maintained across peer tesamorelin listing catalogs, generally keep this distinction intact by discussing tesamorelin strictly within its GHRH-analog classification rather than folding it into a generic peptide category shared with GHS compounds like ipamorelin.

Summary

Tesamorelin vs ipamorelin classification differences trace back to structure and receptor target: tesamorelin is a 44-amino acid GHRH analog acting on the GHRH receptor, while ipamorelin is a five-amino acid GHS/GHRP compound acting on the ghrelin receptor. That split explains why the two are described with different terminology across specification sheets, why their molecular weights differ despite sometimes-similar mg labeling, and why a listing’s use of precise receptor or structural language is a better indicator of classification accuracy than a shared “growth hormone peptide” heading.